GI Dynamics Inc. announced that it has received regulatory approval to begin enrollment in the I-STEP clinical trial in India. I-STEP is a multi-center, randomized, pivotal study evaluating the safety and efficacy of EndoBarrier for glycemic improvement in patients with inadequately controlled type 2 diabetes and obesity and will be conducted exclusively in partnership with the Apollo Hospital System and Apollo Sugar Clinics. This study, which is intended to follow 100 subjects up to 24 months, will evaluate EndoBarrier in patients who fall within a predetermined hemoglobin A1c range.

All enrolled patients will follow a moderate intensity lifestyle and receive dietary counseling, along with standard practice medication management. Diabetes has become a significant health problem in India, with nearly 74 million people suffering from the condition and a proportion of the population that has been undiagnosed. The number of people with diabetes in India is expected to grow to 125 million by 2045.

Obesity is a leading factor for type 2 diabetes, and worryingly, the prevalence of obesity in India is increasing faster than the world average.2 According to an ICMR-INDIAB study, the prevalence rate of obesity and central obesity vary from 11.8% - 31.3% and 16.9% - 36.3% respectively.3 Apollo Sugar is a collaboration between Apollo Health & Lifestyle Limited and Sanofi Ltd. Apollo Sugar is a division of Apollo Hospitals Group (Apollo), focused on the treatment of metabolic disorders, and operates an integrated network of centers of excellence for diabetes, obesity and endocrinology. Apollo has emerged as Asia's foremost integrated healthcare services provider, maintaining a robust presence of hospitals, pharmacies, primary care, secondary-care and diagnostic clinics across the healthcare ecosystem. Since its inception, Apollo has treated patients from 141 countries.

In addition to partnership in the I-STEP clinical trial, GI Dynamics and Apollo Sugar have agreed to work toward setting the terms of a joint-partnership that will focus on the marketing, distribution, and clinical support of EndoBarrier to appropriate patients throughout India and Southeast Asia. Final terms of the proposed collaboration are subject to negotiation and will be disclosed upon completion.